<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00074841</url>
  </required_header>
  <id_info>
    <org_study_id>A0661120</org_study_id>
    <nct_id>NCT00074841</nct_id>
  </id_info>
  <brief_title>Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in India</brief_title>
  <official_title>A Phase II/III, Randomized, Comparative Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in India</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      This primary objective of this study is to assess whether the combination of Azithromycin&#xD;
      with chloroquine is non-inferior to the combination of sulfadoxine-pyrimethamine plus&#xD;
      chloroquine, when used to treat uncomplicated cases of malaria due to Plasmodium falciparum&#xD;
      in adults in India.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">230</enrollment>
  <condition>PLASMODIUM FALCIPARUM MALARIA</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin/Chloroquine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfadoxine-Pyrimethamine/Chloroquine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  Females and males &gt;=18 years of age with uncomplicated, symptomatic malaria as&#xD;
             indicated by the presence of both of the following: a.) Blood smears positive for&#xD;
             Plasmodium falciparum asexual parasitemia between 1000 -100,000 parasites/uL; b.)&#xD;
             Fever or history of fever ( &gt;=38.5C/101.2F rectal or tympanic; &gt;=37.5C/99.5F axillary&#xD;
             or &gt;=38C/100.4F oral) within the prior 24 hours&#xD;
&#xD;
          -  Serum glucose &gt;= 60 mg/dL (by fingerstick or peripheral blood collection)&#xD;
&#xD;
          -  Positive rapid diagnostic test (Binax NOW ICT) positive for P. falciparum&#xD;
&#xD;
          -  Women of childbearing potential must have a negative urine gonadotropin prior to entry&#xD;
             into the study and must agree to use adequate contraception during the entire study&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Severe or complicated malaria including subjects with any of the following: a.)&#xD;
             Impaired consciousness (e.g. obtundation, unarousable coma), seizures or abnormal&#xD;
             neurologic exam suggestive of severe or complicated malaria; b.) Hemoglobinuria; c.)&#xD;
             Jaundice; d.) Respiratory distress (respiratory rate &gt;=30/min); e.) Persistent&#xD;
             vomiting; f.) Hematuria, as reported by the patient&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  History of allergy to or hypersensitivity to azithromycin or any macrolide,&#xD;
             sulfonamides, pyrimethamine, or chloroquine&#xD;
&#xD;
          -  Known or suspected folate deficiency&#xD;
&#xD;
          -  Known history of blood dyscrasias (e.g., megaloblastic anemia, agranulocytosis,&#xD;
             aplastic anemia, thrombocytopenia, leukopenia, neutropenia, hemolytic anemia)&#xD;
&#xD;
          -  Known G-6PD deficiency&#xD;
&#xD;
          -  History of epilepsy or psoriasis&#xD;
&#xD;
          -  History of treatment with any antimalarial drug (chloroquine, quinine, mefloquine,&#xD;
             Malarone, SP, artemisinin compounds) or antibacterial with known antimalarial activity&#xD;
             (macrolides, doxycycline, clindamycin) within 2 weeks prior to enrollment into the&#xD;
             study&#xD;
&#xD;
          -  Known or suspected cardiovascular, hepatic or renal abnormality that in the opinion of&#xD;
             the Investigator would place the subject at increased risk to participate in the&#xD;
             study. The following findings are specific exclusions: a.) Serum creatinine &gt;2.0 x&#xD;
             ULN; b.) ALT and/or AST &gt;3 x ULN&#xD;
&#xD;
          -  Inability to swallow oral medication in tablet form&#xD;
&#xD;
          -  Treatment with other investigational drugs within 30 days prior to enrollment into the&#xD;
             study&#xD;
&#xD;
          -  Alcohol and/or any other drug abuse&#xD;
&#xD;
          -  Requirement to use medication during the study that might interfere with the&#xD;
             evaluation of the study drug&#xD;
&#xD;
          -  Specific systemic diseases or other medical conditions that would interfere with the&#xD;
             evaluation of the therapeutic response or safety of the study drug&#xD;
&#xD;
          -  Inability to comprehend and/or unwillingness to follow the study protocol&#xD;
&#xD;
          -  Prior participation in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dispur Guwahati</city>
        <state>Assam</state>
        <zip>781006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bambolim</city>
        <state>Gao</state>
        <zip>403002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440 018</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Parel Mumbai</city>
        <state>Maharashtra</state>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rourkela</city>
        <state>Orissa</state>
        <zip>769005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <zip>632 004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Indore</city>
        <zip>452001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>December 22, 2003</study_first_submitted>
  <study_first_submitted_qc>December 23, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2003</study_first_posted>
  <last_update_submitted>May 9, 2011</last_update_submitted>
  <last_update_submitted_qc>May 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer</organization>
  </responsible_party>
  <keyword>MALARIA</keyword>
  <keyword>INDIA</keyword>
  <keyword>CHLOROQUINE</keyword>
  <keyword>PLASMODIUM FALCIPARUM</keyword>
  <keyword>SULFADOXINE-PYRIMETHAMINE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
    <mesh_term>Pyrimethamine</mesh_term>
    <mesh_term>Sulfadoxine</mesh_term>
    <mesh_term>Fanasil, pyrimethamine drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

